Patient predictors of response to cognitive behaviour therapy and schema therapy for depression

Carter, Janet D.; McIntosh, Virginia V.W.; Jordan, Jennifer; Porter, Richard; Douglas, Katie; Frampton, Christopher M.; Joyce, Peter R.

doi:10.1177/0004867417750756

Cited by 17 publications

(14 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge, fewer than 10 RCTs have evaluated the effectiveness of individual and/or group schema therapy. RCTs have been conducted with individuals with BPD (Arntz et al, 2022; Farrell et al, 2009; Giesen‐Bloo et al, 2006; Leppänen et al, 2016), personality disorders (Bamelis et al, 2014), binge eating problems (McIntosh et al, 2016), depression (Carter et al, 2018; Porter et al, 2016) and criminal histories (Bernstein et al, 2021). Although the evidence regarding effectiveness based on RCTs is strongest for BPD, well‐designed effectiveness studies across the areas outlined by the panel are needed to improve confidence in expanding the clinical application of the schema therapy model.…”

Section: Discussionmentioning

confidence: 99%

Identifying the research priorities for schema therapy: A Delphi consensus study

Pilkington

Younan

Karantzas

2022

Clin Psychology and Psychoth

View full text Add to dashboard Cite

Despite the popularity of schema therapy, there exist several important gaps in research on the schema therapy model and its effectiveness. The number of gaps makes it difficult to determine the research areas of the highest strategic priority to advance schema therapy. The objective of this study was to establish consensus among schema therapy clinicians and researchers on the priority areas for future schema therapy research. A panel of experts in schema therapy (43 clinicians and 13 researchers) participated in a Delphi consensus study. The research areas rated were developed by interviewing the founder of schema therapy, Jeffrey Young, conducting a focus group with the executive board of the International Society for Schema Therapy and screening recent reviews on schema therapy for recommendations for future research. The panel rated 81 research areas in terms of priority across three rounds. Nineteen research areas were rated by 75% of the panel as ‘Very high priority’ or ‘High priority’. These priorities reflected four broad themes: (1) schema therapy constructs and measures, (2) the theoretical assumptions underlying schema therapy, (3) schema therapy and theory in relation to different contexts and outcomes and (4) schema therapy effectiveness and mechanisms of change. The findings are important for establishing a clear research agenda for the future of schema therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Identifying the research priorities for schema therapy: A Delphi consensus study

Pilkington

Younan

Karantzas

2022

Clin Psychology and Psychoth

View full text Add to dashboard Cite

show abstract

“…The effectiveness of Schema Therapy on psychological health has been documented. There is strong support from randomized clinical trials examining the efficacy of Schema Therapy for depression (Carter et al, 2018; Renner et al, 2013), anxiety (Peeters et al, 2021), and improving psychological well-being (Mohammad Nezhady & Rabiei, 2015) on clients with a history of interpersonal trauma. A study by Renner et al (2016), found that compared to the no-treatment control group, the intervention group had a significant large effect on depressive symptoms.…”

Section: Cultural Contextmentioning

confidence: 99%

Effectiveness of Compassion-Based Acceptance Therapy and Schema Therapy on Intimate Partner Violence Victims’ Psychological Health

Nikparvar,

Sasanian,

Spencer

et al. 2023

J Interpers Violence

View full text Add to dashboard Cite

The aim of this study was to examine the effectiveness of group Compassion-Based Acceptance and Commitment Therapy (ACT) and group Schema Therapy on depression, stress, psychological well-being, and resiliency in female intimate partner violence (IPV) victims in Iran. For this purpose, a sample of 60 women who reported ongoing experiences of IPV were selected. Out of these 60 women, 20 were randomly assigned to the ACT treatment group, 20 to the Schema Therapy group, and 20 to the no-treatment control group. Five participants withdrew from each group. For both the ACT and Schema groups, depression and stress decreased, and overall well-being and resiliency scores significantly increased between pre-test and post-test, and there was not a significant difference in depression levels between post-test and the follow-up for either group. For the control group, depression and resiliency scores did not significantly change between pre-test and post-test or between the post-test and follow-up. Stress scores significantly decreased between pre-test and post-test, but stress scores significantly increased between the post-test and the follow-up. Well-being scores significantly increased between pre-test and post-test and did not significantly change between post-test and follow-up. One-way analyses of variance examining change scores of depression, stress, overall well-being, and resiliency between the pre-test and the follow-up found that the ACT and Schema group’s depression and stress levels lowered, and resiliency levels increased significantly more than the control group. There was no significant difference in depression and resiliency change score for the ACT and Schema group. The ACT group’s overall well-being increased significantly more than the control group.

show abstract

“…Cognitive impairment plays a key role as a transdiagnostic factor in psychiatric disorders in general and MDD in particular [ 146 – 148 ]. These deficits affect different cognitive domains such as memory, executive functions, attention, and learning [ 149 , 150 ] and in many cases outlast the remission of depressive symptoms [ 151 , 152 ].…”

Section: Measures and Hypothesesmentioning

confidence: 99%

Schema therapy versus cognitive behavioral therapy versus individual supportive therapy for depression in an inpatient and day clinic setting: study protocol of the OPTIMA-RCT

et al. 2020

View full text Add to dashboard Cite

Background Major depressive disorder represents (MDD) a major cause of disability and disease burden. Beside antidepressant medication, psychotherapy is a key approach of treatment. Schema therapy has been shown to be effective in the treatment of psychiatric disorders, especially personality disorders, in a variety of settings and patient groups. Nevertheless, there is no evidence on its effectiveness for MDD in an inpatient nor day clinic setting and little is known about the factors that drive treatment response in such a target group. Methods In the current protocol, we outline OPTIMA (OPtimized Treatment Identification at the MAx Planck Institute): a single-center randomized controlled trial of schema therapy as a treatment approach for MDD in an inpatient and day clinic setting. Over the course of 7 weeks, we compare schema therapy with cognitive behavioral therapy and individual supportive therapy, conducted in individual and group sessions and with no restrictions regarding concurrent antidepressant medication, thus approximating real-life treatment conditions. N = 300 depressed patients are included. All study therapists undergo a specific training and supervision and therapy adherence is assessed. Primary outcome is depressive symptom severity as self-assessment (Beck Depression Inventory-II) and secondary outcomes are clinical ratings of MDD (Montgomery-Asberg Depression Rating Scale), recovery rates after 7 weeks according to the Munich-Composite International Diagnostic Interview, general psychopathology (Brief Symptom Inventory), global functioning (World Health Organization Disability Assessment Schedule), and clinical parameters such as dropout rates. Further parameters on a behavioral, cognitive, psychophysiological, and biological level are measured before, during and after treatment and in 2 follow-up assessments after 6 and 24 months after end of treatment. Discussion To our knowledge, the OPTIMA-Trial is the first to investigate the effectiveness of schema therapy as a treatment approach of MDD, to investigate mechanisms of change, and explore predictors of treatment response in an inpatient and day clinic setting by using such a wide range of parameters. Insights from OPTIMA will allow more integrative approaches of psychotherapy of MDD. Especially, the identification of intervention-specific markers of treatment response can improve evidence-based clinical decision for individualizing treatment. Trial registration Identifier on clinicaltrials.gov: NCT03287362; September, 12, 2017

show abstract

Patient predictors of response to cognitive behaviour therapy and schema therapy for depression

Cited by 17 publications

References 38 publications

Identifying the research priorities for schema therapy: A Delphi consensus study

Identifying the research priorities for schema therapy: A Delphi consensus study

Effectiveness of Compassion-Based Acceptance Therapy and Schema Therapy on Intimate Partner Violence Victims’ Psychological Health

Schema therapy versus cognitive behavioral therapy versus individual supportive therapy for depression in an inpatient and day clinic setting: study protocol of the OPTIMA-RCT

Contact Info

Product

Resources

About